News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Takeda Pharmaceutical stock has returned 91.4% over the past 5 years and appears undervalued on market multiples, yet broader valuation checks are mixed. The company's P/S ratio of 2.0x is below the model-based fair ratio of 3.4x, suggesting it's undervalued on sales despite recent …
Sharemaestro market context Price above Trend Line 52 weeks +27.3%Takeda Pharmaceutical (TSE:4502) has released positive Phase 3 data for its oral TYK2 inhibitor zasocitinib for plaque psoriasis, which has contributed to recent share price momentum. Despite this, the stock trades below analyst price targets and some intrinsic value estimates, suggesting it may be …
Sharemaestro market context Price above Trend Line 52 weeks +27.3%Take-Two Interactive has projected fiscal 2027 net bookings to reach $8.0 billion to $8.2 billion, a 20% increase directly attributed to the confirmed November 19 launch of Grand Theft Auto VI. This guidance has led to a significant re-evaluation of Take-Two stock, with TIKR's …
The article provides an overview of institutional shareholding in STAK, detailing the number of shares held by various firms and any changes in their holdings. Key institutional investors include Lanying Capital Ltd, MT. Yang Holding Ltd, Citadel Advisors LLC, and XTX Markets LLC. The …
BTIG Research has reaffirmed its "buy" rating for Take-Two Interactive Software (NASDAQ:TTWO), setting a price target of $293, which suggests a 26.48% upside. The consensus among analysts is a "Moderate Buy" with an average price target of $294.44. Insider trading activity shows significant sales, …
Sharemaestro market context Trend signal active 52 weeks -2.8%SummitTX Capital L.P. decreased its stake in Take-Two Interactive Software by 20.7% in the first quarter, selling 11,261 shares and retaining 43,165 shares valued at approximately $8.5 million. Meanwhile, institutional investors collectively own 95.46% of the company's stock, while insiders have sold a significant …
Delta Global Management LP significantly increased its stake in Take-Two Interactive Software, Inc. (NASDAQ:TTWO) by over 600% in the first quarter, according to a recent SEC filing. The company's stock performance and valuations are detailed, alongside analyst ratings which generally recommend a "Moderate Buy". …
This article from OpenSecrets details the lobbying activities of Takeda Pharmaceutical Co in 2025. It lists the 30 lobbyists hired by the company, including information on their firms and whether they previously worked in the federal government. The report indicates that 19 of the …
In July 2026, Takeda announced new Phase 3 data for its oral TYK2 inhibitor zasocitinib (TAK-279) in adults with moderate-to-severe plaque psoriasis, showing consistently high rates of skin clearance across difficult areas such as the scalp, nails, palms and soles compared with placebo. The …
Tiger Global Management LLC significantly reduced its stake in Take-Two Interactive Software (NASDAQ:TTWO) by 65.7% in the first quarter, yet still holds 2 million shares valued at approximately $395 million. Despite this reduction, institutional ownership remains very high at 95.46%, with major investors like …
Epoch Investment Partners Inc. has reduced its stake in Take-Two Interactive Software, Inc. (NASDAQ:TTWO) by 27.0%, selling 31,192 shares in the first quarter, bringing their total holdings to 84,344 shares valued at $16.66 million. This comes amidst other institutional investor activities and significant insider …
Caxton Associates LLP significantly reduced its stake in Take-Two Interactive Software (NASDAQ:TTWO) in the first quarter, selling 13,077 shares and ending the period with 7,211 shares valued at approximately $1.42 million. Several company insiders, including President Karl Slatoff and Daniel P. Emerson, also sold …
Allspring Global Investments Holdings LLC significantly reduced its stake in Take-Two Interactive Software (NASDAQ:TTWO) by selling 110,083 shares, decreasing its ownership by 92.0% in the first quarter. Despite this, other institutional investors have recently bought shares, and analysts maintain a "Moderate Buy" consensus rating …
Takeda Pharmaceutical is expanding its presence in Indonesia through a multi-year collaboration with the government to develop plasma collection and biopharmaceutical manufacturing. Concurrently, the company announced positive Phase 3 data for its TYK2 inhibitor zasocitinib for plaque psoriasis, showing high skin clearance rates. These …
US equities closed mixed on Friday, with the Dow Jones Industrial Average rising 0.45%, the S&P 500 gaining 0.05%, and the NASDAQ Composite declining 0.64%. Gains in telecommunications, financials, and healthcare sectors boosted the Dow, while technology, utilities, and oil & gas sectors pulled …
Takeda Pharmaceutical Co Ltd (0RN3) has released its Q3 2025 earnings report, showing an actual EPS of €0.35, beating the consensus of €0.23 by €0.12. The company's actual revenue was €6.39 billion, slightly missing the expected revenue of €6.39 billion, with a year-over-year revenue …
Takeda Pharmaceutical (TAK.US) is scheduled to release its earnings report on July 30. Investors and analysts will be closely watching the report for insights into the company's financial performance. This announcement provides a specific date for the upcoming financial disclosure.
Takeda Pharmaceutical Co., Ltd. (OTC:TKPHF) generated 28.38 billion USD in revenue last year. Its top-performing segment was Digestive System Diseases, contributing 8.86 billion USD, and the United States was the largest regional contributor with 13.63 billion USD. This data provides a breakdown of the …
This article provides an income statement and earnings report for STAK INC. (STAK). It details the company's financial performance, including revenue, expenses, and net income, offering key insights into its profitability and operational efficiency.
Inceptionr LLC significantly increased its stake in Take-Two Interactive Software (NASDAQ:TTWO) by 650.6% in the first quarter, now owning 8,820 shares worth $1.74 million. Other institutional investors like Norges Bank, AQR Capital Management LLC, and Alyeska Investment Group also made substantial acquisitions, indicating strong …
Sharemaestro market context Trend signal active 52 weeks +7.8%China Merchants has initiated coverage on Takeda Pharmaceutical with a "Buy" rating and set a price target of 6,600 Yen. This recommendation indicates a positive outlook from the firm regarding Takeda's stock performance. The article also mentions recent news about Takeda's dengue vaccine approval …
This Yahoo Finance page provides a comprehensive overview of Take-Two Interactive Software, Inc. (TTWO) stock, including its current price, historical data, news, financial performance, and analyst ratings. A significant focus is on the upcoming release of Grand Theft Auto VI, with several news articles …
Takeda Pharmaceutical Co Ltd (TAK) shows stable fundamentals, high growth potential, and is considered fairly valued within the Pharmaceuticals industry. Institutional ownership is high, and analysts recommend "Buy" with a target price of $21.13. The stock is currently trading sideways, suggesting suitability for range-bound …
Take-Two Interactive Software, Inc. (NASDAQ:TTWO) has received a "Moderate Buy" consensus rating from analysts, with an average 1-year price target of $294.44. Recent analyst reports have been largely positive, increasing price targets and reaffirming "Buy" or "Overweight" ratings. However, insiders including President Karl Slatoff …
Assetmark Inc. significantly increased its stake in Takeda Pharmaceutical Co. by 45.8% in the first quarter of 2026, holding 227,616 shares valued at $4.2 million. Other institutional investors like Royal Bank of Canada and Goldman Sachs also boosted their holdings, contributing to hedge funds …
Takeda Pharmaceutical (NYSE:TAK) is scheduled to announce its Q1 2027 earnings before market open on Thursday, July 30th. Analysts are forecasting earnings of $0.1689 per share and revenue of $7.1469 billion for the quarter. The company's stock currently has an average "Hold" rating from …
Takeda's China unit has received approval from China's National Medical Products Administration for ORZEYFUL (oveporexton) to treat narcolepsy type 1 in patients aged 16 and older. This drug is the first approved selective orexin 2 receptor agonist in China, targeting the underlying orexin deficiency …
Takeda has received the first global approval for its orexin agonist, oveporexton (Orzeyful), in China for treating narcolepsy type 1 in adults and adolescents aged 16 and over. This approval represents a significant shift from symptomatic treatment to a mechanism-driven approach for narcolepsy, addressing …
Search by ticker symbol or company name and select a result to open its chart. The US only control limits results to active US-listed stocks and ETFs.
Showing active US-listed stocks and ETFs only.